Jacqueline C. Barrientos, MD, MS, discusses exciting novel combination strategies that are being presented at the 2019 ASH Annual meeting.
Jacqueline C. Barrientos, MD, MS
Advertisement
Articles by Jacqueline C. Barrientos, MD, MS
Jacqueline C. Barrientos, MD, MS, discusses the role of acalabrutinib, a second-generation BTK inhibitor, that is available for patients with chronic lymphocytic leukemia, but not yet approved.
Advertisement
Latest Updated Articles
Using Acalabrutinib in CLL Patients With Ibrutinib IntolerancePublished: March 11th 2019 | Updated:
Novel Combination Strategies in CLLPublished: December 8th 2019 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5
